$14.33
0.92%
Nasdaq, Dec 05, 10:00 pm CET
ISIN
US0465131078
Symbol
ATRA

Atara Biotherapeutics Inc Stock price

$14.33
+3.58 33.30% 1M
+5.91 70.19% 6M
+1.02 7.66% YTD
+1.82 14.55% 1Y
-101.92 87.67% 3Y
-641.42 97.81% 5Y
-833.67 98.31% 10Y
-251.92 94.62% 20Y
Nasdaq, Closing price Fri, Dec 05 2025
+0.13 0.92%
ISIN
US0465131078
Symbol
ATRA
Industry

Key metrics

Basic
Market capitalization
$103.3m
Enterprise Value
$131.3m
Net debt
$27.9m
Cash
$13.7m
Shares outstanding
7.2m
Valuation (TTM | estimate)
P/E
8.3 | 6.7
P/S
0.7 | 0.9
EV/Sales
0.9 | 1.1
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-89.2%
Return on Equity
87.8%
ROCE
344.2%
ROIC
275.4%
Debt/Equity
-1.1
Financials (TTM | estimate)
Revenue
$151.9m | $121.4m
EBITDA
$44.9m | $29.6m
EBIT
$41.7m | $18.8m
Net Income
$23.4m | $15.4m
Free Cash Flow
$-69.8m
Growth (TTM | estimate)
Revenue
51.3% | -5.9%
EBITDA
139.3% | 140.4%
EBIT
134.9% | 124.0%
Net Income
117.6% | 118.0%
Free Cash Flow
26.4%
Margin (TTM | estimate)
Gross
81.6%
EBITDA
29.5% | 24.4%
EBIT
27.4%
Net
15.4% | 12.7%
Free Cash Flow
-45.9%
More
EPS
$1.7
FCF per Share
$-9.7
Short interest
3.0%
Employees
153
Rev per Employee
$840.0k
Show more

Is Atara Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Atara Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Atara Biotherapeutics Inc forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Atara Biotherapeutics Inc forecast:

Buy
80%
Hold
20%

Financial data from Atara Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
152 152
51% 51%
100%
- Direct Costs 28 28
61% 61%
18%
124 124
49% 49%
82%
- Selling and Administrative Expenses 29 29
26% 26%
19%
- Research and Development Expense 53 53
67% 67%
35%
45 45
139% 139%
30%
- Depreciation and Amortization 3.17 3.17
39% 39%
2%
EBIT (Operating Income) EBIT 42 42
135% 135%
27%
Net Profit 23 23
118% 118%
15%

In millions USD.

Don't miss a Thing! We will send you all news about Atara Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Atara Biotherapeutics Inc Stock News

Neutral
Business Wire
25 days ago
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2025 and business updates. Tabelecleucel (tab-cel® or Ebvallo™) f...
Neutral
PRNewsWire
about one month ago
Tabelecleucel BLA currently under U.S. Food and Drug Administration (FDA) Priority Review as potentially the first approved therapy in the U.S. for EBV+ PTLD with a Prescription Drug User Fee Act (PDUFA) target action date of January 10, 2026 First allogeneic T-Cell therapy BLA offers hope to EBV+ PTLD patients who have limited treatment options and lifespan measured in only a few weeks to mont...
Neutral
Business Wire
3 months ago
THOUSAND OAKS, Calif--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Greg Ciongoli will assume the role of Chair of the Board of Directors. Greg Ciongoli is the founder ...
More Atara Biotherapeutics Inc News

Company Profile

Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.

Head office United States
CEO Anhco Nguyen
Employees 153
Founded 2012
Website www.atarabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today